Roche acquired 11.7 billion yuan to expand the scope of hospital business

Medical Network, March 17 News,
New Business Supplement Product Line
On March 15, according to Reuters, Roche said it would acquire GenMark Diagnostics, a US molecular diagnostic company, for US$1.
8 billion (approximately RMB 11.
7 billion)
.
The report pointed out that Roche has acquired GenMark Diagnostics, a molecular diagnostic company headquartered in the United States, which fills the gap in Roche-related products
.
The Swiss drugmaker said the deal will be one of the fastest-growing diagnostic areas
.
In terms of details, Roche made a cash offer for GenMark at a price of US$24.
05 per share.
The transaction should be completed in the second quarter
.
Reuters reported that GenMark conducts a "comprehensive physical examination" to simultaneously detect multiple pathogens that cause respiratory diseases , such as pneumonia or dangerous blood infections and sepsis
.
Roche has tried to enter this field to benchmark its competitors
.

　　Expansion of the hospital’s business scope
For this acquisition, Roche’s head of diagnostics Thomas Schinecker quoted industry data as saying that the market for such tests in 2019 was US$800 million per year, adding that the market should grow at a rate of 20% per year until 2024.
It will reach US$2 billion annually
.
He estimated that GenMark currently has a 7% market share, but Roche's goal is to continue to increase significantly from now to the next four years
.
Schinecker said in an interview: "We can use our commercial strength to operate, and we also believe that we can use our manufacturing skills to open up a good situation, expand scale and reduce costs.

.
Analysts said that this move will expand Roche's scope of business in hospitals, and its existing focus is on centralized laboratories
.
UBS (UBS) analysts wrote: "This will have broader strategic significance in the hospital (may choose to conduct more tests within the company)
.
" At present, this cooperation has been approved by the boards of directors of the two companies .
, And this acquisition is also a relatively large-scale acquisition of Roche in recent years
.
Roche pointed out in the statement that the addition of GenMark's ePlex platform can solve a wider range of infectious disease detection needs.
At the same time, Roche said that the sales teams of large pharmaceutical companies can make products have more international audiences in terms of products
.
According to the official website, GenMark Diagnostics was established in 2010 and is headquartered in San Diego, USA.
It is a molecular diagnostics company
.
The company's proprietary technology and detection eSensor ePlex, eSensorXT-8 system
.

　　The domestic track continued to extend the
line of sight and turned back to China, and the cooperation is still going on
.
On March 3, 2021, Roche Diagnostics Life Sciences and Yunkang Group formally announced that they have reached a further strategic cooperation.
The two parties stated that they will make full use of their respective technical reserves and advantages in the field of precision medicine to deepen the development and application of genetic sequencing technology.
Full cooperation
.
Yuan Jianzhong, vice president of life sciences at Roche Diagnostics China, said that precision medicine, diagnosis first, with the conclusion of this strategic cooperation, Roche Diagnostics will jointly explore next-generation sequencing solutions in tumors , genetic diseases, infections, and pharmacogenomics.
Product development, application and commercialization in the field of precision medicine such as science and reproductive health
.
Zhang Yong, President of Yunkang Group, said that this cooperation with Roche Diagnostics will bring us advanced next-generation sequencing solutions
.
According to official website information, in August 2000, Roche Diagnostics (Shanghai) Co.
, Ltd.
was established as a wholly foreign-owned company in the Waigaoqiao Free Trade Zone in Shanghai to carry out business in Mainland China
.
Yunkang Group is a high-tech enterprise group engaged in professional medical services, public health services and related technical support services from Sun Yat-sen University.
It is a core member and executive unit of Sun Yat-sen University's medical science and technology service system
.
In February 2021, Roche Diagnostics China and SARSTEDT of Germany announced a strategic cooperation to jointly promote the application of the Tempus600 automated sample transmission system under the German SARSTEDT in the Chinese market
.
The system can be seamlessly connected with the Roche Diagnostics CCM laboratory automation solution to truly realize the non-contact full-process automation from sample transmission to result report, help intelligent laboratories, and promote the quality, efficiency and experience of inspection and diagnosis and treatment.
Optimization
.
In 2020, Roche announced that it will further increase its investment in its Roche Diagnostics Asia-Pacific production base and R&D center in Suzhou Industrial Park.
The planned total investment is 180 million U.
S.
dollars, and the total investment is 479 million U.
S.
dollars (approximately RMB 3.
1 billion).
The capital increase will further deepen Roche Diagnostics' strategic layout in China
.
The new investment will be used for various in vitro diagnostic reagent production and construction and product line transfer projects including tissue diagnostic staining platform reagents and professional diagnostic reagents
.
According to the information on its official website, in the fight against the global COVID-19 epidemic, Roche Diagnostics developed and provided cobas SARS-CoV-2 nucleic acid qualitative testing and Elecsys® Anti-SARS-CoV-2 antibody testing
.